CERo Therapeutics Holdings, Inc. (CEROW) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CERo Therapeutics Holdings, Inc. (CEROW) trades at $0.0017. CERo Therapeutics Holdings, Inc. is an immunotherapy company focused on developing engineered T cell therapeutics for cancer treatment. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for CEROW: CEROW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CEROW against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on CEROW.
How is this calculated? →CERo Therapeutics Holdings, Inc. (CEROW) Healthcare & Pipeline Overview
CERo Therapeutics Holdings, Inc. is a biotechnology company specializing in the development of engineered T-cell therapies for cancer, particularly hematologic malignancies. Their innovative approach targets the 'Eat Me' signal on tumor cells, positioning them within the competitive immunotherapy landscape.
What Is the Investment Thesis for CEROW?
CERo Therapeutics Holdings, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on engineered T cell therapies targeting the 'Eat Me' signal in hematologic malignancies offers a novel approach with the potential for significant clinical impact. Key value drivers include the successful advancement of their lead program through preclinical and clinical development, securing strategic partnerships, and demonstrating superior efficacy compared to existing treatments. However, the company's early stage of development, limited financial resources (Market Cap: $0.00B), and the inherent risks associated with drug development pose substantial challenges. The negative profit margin of -1215.6% highlights the need for significant future funding. Successful clinical trials and regulatory approvals are critical for realizing the company's potential.
Based on FMP financials and quantitative analysis
CEROW Key Highlights
Focus on engineered T cell therapeutics for cancer treatment, specifically hematologic malignancies.
- Lead program targets the 'Eat Me' signal upregulated on B cell and myeloid tumors.
- Based in South San Francisco, a hub for biotechnology innovation.
- Early-stage development company focused on preclinical research and development.
- Gross Margin of -19.6% indicates significant costs associated with research and development.
Who Are CEROW's Competitors?
CEROW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AIMD Ainos, Inc. | $1.45 | -2.03% | $10.7M | — |
| BDRX Biodexa Pharmaceuticals Plc | $1.26 | +0.00% | 39 | |
| BIVI BioVie Inc. | $1.86 | +38.81% | $14.0M | — |
| CMMB Chemomab Therapeutics Ltd. | $2.07 | -0.96% | $12.7M | 49 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CEROW's Key Strengths?
Novel approach targeting the 'Eat Me' signal in cancer cells.
- Expertise in engineered T cell therapy development.
- Potential for personalized medicine applications.
- Strategic location in a biotechnology hub.
What Are CEROW's Weaknesses?
Early-stage development with limited clinical data.
- Dependence on external funding and partnerships.
- Small team size and limited resources (8 employees).
- Negative profit margin and limited revenue.
What Could Drive CEROW Stock Higher?
Preclinical data release demonstrating efficacy of lead program.
- Initiation of Phase 1 clinical trial for lead program.
- Securing strategic partnerships with pharmaceutical companies.
- Expansion of intellectual property portfolio.
What Are the Key Risks for CEROW?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or unexpected side effects.
- Regulatory delays or rejection of therapy approval.
- Competition from established players in the immunotherapy market.
- Dependence on external funding and partnerships.
- Patent disputes or intellectual property infringement.
What Are the Growth Opportunities for CEROW?
- Expansion into new therapeutic areas: CERo Therapeutics has the potential to expand its engineered T cell therapy platform to target solid tumors and other cancer types beyond hematologic malignancies. This expansion could significantly increase the company's addressable market, as solid tumors represent a substantial portion of cancer cases. Success in this area would require further research and development to identify appropriate targets and engineer T cells for effective tumor penetration and destruction. The market for solid tumor therapies is estimated to be substantial, offering a significant growth opportunity for CERo.
- Strategic partnerships and collaborations: Collaborating with larger pharmaceutical companies or research institutions could provide CERo with access to additional funding, expertise, and resources to accelerate the development and commercialization of its therapies. Strategic partnerships could also facilitate entry into new markets and expand the company's reach. Securing such partnerships will be crucial for CERo to compete effectively with larger players in the immunotherapy space. These partnerships could be formed within the next 1-3 years.
- Advancement of lead program through clinical trials: The successful progression of CERo's lead program through clinical trials is critical for demonstrating the safety and efficacy of its engineered T cell therapy. Positive clinical trial results would not only validate the company's technology but also attract further investment and partnerships. The timeline for clinical trials can vary, but typically involves several phases over a period of years. Achieving positive outcomes in these trials is a key milestone for CERo's growth.
- Securing intellectual property protection: Obtaining and maintaining strong intellectual property protection for its engineered T cell therapy platform is essential for CERo to maintain a competitive advantage. Patents can provide exclusive rights to the company's technology, preventing competitors from developing similar therapies. A robust IP portfolio can also increase the company's attractiveness to potential partners and investors. CERo should actively pursue patent applications and defend its existing intellectual property rights.
- Personalized medicine approach: CERo can explore the development of personalized T cell therapies tailored to individual patients' specific tumor characteristics. This approach involves analyzing a patient's tumor to identify unique targets and then engineering T cells to specifically attack those targets. Personalized medicine has the potential to significantly improve treatment outcomes and reduce side effects. However, it also requires advanced diagnostic capabilities and manufacturing processes. The market for personalized cancer therapies is growing rapidly, offering a significant opportunity for CERo.
What Are CEROW's Competitive Advantages?
- Proprietary engineered T cell technology targeting the 'Eat Me' signal.
- Strong intellectual property protection through patents.
- Expertise in T cell engineering and cancer immunotherapy.
- Potential for personalized medicine approach tailored to individual patients.
What Does CEROW Do?
CERo Therapeutics Holdings, Inc., founded to revolutionize cancer treatment, is an immunotherapy company dedicated to advancing the development of engineered T cell therapeutics. The company's primary focus is on creating innovative therapies for hematologic malignancies. Their lead program targets an 'Eat Me' signal, a mechanism upregulated on B cell and myeloid tumors that allows cancer cells to evade the immune system. By engineering T cells to recognize and attack this signal, CERo aims to provide more effective and targeted cancer treatments. Based in South San Francisco, California, a hub for biotechnology innovation, CERo is strategically positioned to attract top talent and collaborate with leading research institutions. The company is currently in the early stages of development, focusing on preclinical research and development to advance its lead program towards clinical trials. CERo's commitment to pioneering T cell therapies underscores its mission to improve outcomes for patients battling cancer. The company's approach reflects a growing trend in cancer immunotherapy, leveraging the body's own immune system to fight the disease.
What Products and Services Does CEROW Offer?
- Develop engineered T cell therapeutics for cancer treatment.
- Target the 'Eat Me' signal on cancer cells to enhance immune response.
- Focus on hematologic malignancies, such as B cell and myeloid tumors.
- Conduct preclinical research and development to advance therapies.
- Seek to improve outcomes for patients battling cancer through innovative immunotherapy.
- Pioneer T cell therapies leveraging the body's own immune system.
How Does CEROW Make Money?
- Develop and patent novel engineered T cell therapies.
- Out-license or partner with pharmaceutical companies for clinical development and commercialization.
- Potentially manufacture and sell therapies directly, pending regulatory approval.
- Generate revenue through upfront payments, milestone payments, and royalties.
What Industry Does CEROW Operate In?
CERo Therapeutics Holdings, Inc. operates within the rapidly evolving biotechnology industry, specifically in the cancer immunotherapy market. This market is characterized by intense competition and a high degree of innovation, with companies racing to develop more effective and targeted cancer treatments. CERo's focus on engineered T cell therapies aligns with a key trend in the industry, leveraging the body's own immune system to fight cancer. Competitors like AIMD, BDRX, BIVI, CMMB, and GLMD are also active in the immunotherapy space, highlighting the competitive landscape.
Who Are CEROW's Key Customers?
- Cancer patients suffering from hematologic malignancies.
- Hospitals and oncology clinics providing cancer treatment.
- Pharmaceutical companies seeking to expand their oncology portfolios.
- Research institutions and universities involved in cancer research.
Company Profile
CERo Therapeutics Holdings, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO Christopher Ehrlich. CEROW has traded publicly since 2024.
Financial Health
CERo Therapeutics Holdings, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Forward Outlook
Wall Street analysts project CERo Therapeutics Holdings, Inc. revenue of about $0 for fiscal 2026, with EPS near $-2.50.
CEROW Financials
Bull Case vs Bear Case
Bull Case
- Novel approach targeting the 'Eat Me' signal in cancer cells.
- Expertise in engineered T cell therapy development.
- Potential for personalized medicine applications.
- Strategic location in a biotechnology hub.
Bear Case
- Early-stage development with limited clinical data.
- Dependence on external funding and partnerships.
- Small team size and limited resources (8 employees).
- Negative profit margin and limited revenue.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
CEROW Latest News
No recent news available for CEROW.
CEROW Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CEROW.
Price Targets
Wall Street price target analysis for CEROW.
CEROW MoonshotScore
What does this score mean?
The MoonshotScore rates CEROW 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Christopher Ehrlich
CEO
Christopher Ehrlich serves as the CEO of CERo Therapeutics Holdings, Inc. His background encompasses experience in managing and leading biotechnology companies, with a focus on early-stage development. He brings a strategic vision to the company, guiding its efforts in developing innovative cancer therapies. His leadership is crucial for navigating the complexities of the biotechnology industry and securing funding for research and development. He is responsible for the overall direction and performance of the company.
Track Record: As CEO, Christopher Ehrlich is focused on advancing CERo's lead program through preclinical development and preparing for clinical trials. His strategic decisions are centered on securing partnerships, attracting investment, and building a strong team. His leadership is essential for achieving key milestones and driving the company's growth. He manages a small team of 8 employees.
CEROW OTC Market Information
CEROW trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
Common Questions About CEROW (Healthcare)
What does CERo Therapeutics Holdings, Inc. do?
CERo Therapeutics Holdings, Inc. is a biotechnology company focused on developing innovative engineered T cell therapies for the treatment of cancer. The company's lead program targets the 'Eat Me' signal, which is upregulated on B cell and myeloid tumors, allowing cancer cells to evade the immune system.
What do analysts say about CEROW stock?
As of March 17, 2026, there is no available analyst coverage for CEROW stock. The company's small market capitalization ($0.00B) and early stage of development may limit analyst interest. Investors should conduct their own due diligence and consider the company's financial position, clinical trial progress, and competitive landscape before making any investment decisions. Key valuation metrics are currently unavailable due to the company's lack of revenue and earnings.
What are the main risks for CEROW?
CERo Therapeutics Holdings, Inc. faces several key risks inherent to the biotechnology industry. These include the risk of clinical trial failures, regulatory hurdles, and competition from established players. The company's dependence on external funding and partnerships also poses a risk, as access to capital may be limited. Additionally, patent disputes and intellectual property infringement could threaten the company's competitive advantage.
What are the key factors to evaluate for CEROW?
Evaluate CEROW on fundamentals, analyst consensus, and risk factors. CERo Therapeutics Holdings, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. Not financial advice.
How frequently does CEROW data refresh on this page?
CEROW's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CEROW's recent stock price performance?
CERo Therapeutics Holdings, Inc. (CEROW) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel approach targeting the 'Eat Me' signal in cancer cells. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CEROW overvalued or undervalued right now?
CERo Therapeutics Holdings, Inc. (CEROW) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research CEROW before investing?
Before investing in CERo Therapeutics Holdings, Inc. (CEROW), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- AI analysis is pending and may provide further insights.